Close Menu

transcriptomics

Decipher will remain a wholly owned subsidiary of Veracyte, which plans to integrate Decipher's urologic cancer tests on its nCounter platform.

Investigators reported that the classifier could correctly predict cancer type with over 94 percent accuracy and highlighted impacts in a commercially tested cohort.

FLEX will include full transcriptome data paired with 800 data points from 10,000 patients, offering researchers the chance to study diverse patient subsets.

The partners will apply whole-exome and whole-transcriptome analysis to evaluate two existing drugs for squamous cell carcinoma treatment.

The funds will support continued growth in precision oncology, new product development, and new initiatives in the clinical trial and biopharmaceutical markets.

A new study found that FOXA1 missense mutations were enriched in metastatic breast tumors and were associated with lower response to aromatase inhibitors. 

WUSTL will evaluate BostonGene's software, which integrates data from NGS with immunofluorescence imaging to profile tumors and their microenvironments.

The company has formalized an existing relationship by acquiring Pharmatech, hoping to directly integrate the firm's "right on time" trial matching service with its own molecular testing.

Mismatch repair-deficient tumors with many insertion-deletion mutations and enhanced microsatellite instability responded better to anti-PD-1 immunotherapy.

While the study didn't meet its primary endpoint, it showed the potential of transcriptomics to match cancer patients to beneficial treatments.

Pages